The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 29, 2021

Filed:

May. 21, 2018
Applicant:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Inventors:

Eric Pamer, Montclair, NJ (US);

Jedd D. Wolchok, New York, NY (US);

Krista Dubin, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 63/00 (2020.01); A61K 35/742 (2015.01); A61K 45/06 (2006.01); G01N 33/569 (2006.01); A23L 5/00 (2016.01); A61P 1/00 (2006.01); A61K 9/00 (2006.01); A61K 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/742 (2013.01); A23L 5/00 (2016.08); A61K 9/0031 (2013.01); A61K 9/0043 (2013.01); A61K 9/0053 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); G01N 33/56911 (2013.01); A61K 2035/115 (2013.01); G01N 2800/067 (2013.01);
Abstract

The present invention relates to methods and compositions for identifying subjects treated with or considered for treatment with checkpoint blockade therapeutic agents that are at higher or lower risk for developing checkpoint therapy associated colitis, by analyzing the intestinal microbiome of those subjects. It is based, at least in part, on the discovery that the abundance of certain intestinal microbiota of the phyla Bacteroidetes, including the bacteria in the families Bacteroidaceae, Rikenellaceae, and Barnesisllaceae, and/or an increase or decrease in microbial genetic pathways involved in polyamine transport and/or B vitamin biosynthesis (e.g., (riboflavin (B2), pantothenate (B5) and thiamine (B1)) are associated with the likelihood of developing checkpoint therapy associated colitis.


Find Patent Forward Citations

Loading…